Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.

Tas F., Camlica H., Kurul S., Aydiner A., Topuz E.

Clinical oncology (Royal College of Radiologists (Great Britain)), vol.15, no.3, pp.132-5, 2003 (SCI-Expanded) identifier identifier identifier


Aim: The aim of the current trial was to assess the efficacy and toxicity of 3-weekly intravenous docetaxel and irinotecan in the treatment of patients with metastatic malignant melanoma.